|
GB202015399D0
|
|
Engineered extracellular vesicles displaying enhanced pharmacokinetics
|
|
GB202010278D0
|
|
Extracellular vesicles with improved half-life
|
|
GB201916884D0
|
|
Nanoparticle-like delivery system
|
|
WO2020099682A1
|
|
Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
|
|
GB201906482D0
|
|
Exosome comprising stabilized RNA therapeutics
|
|
GB201818760D0
|
|
Extracellular vesicles for replacement of ureancycle proteins & nucleic acids
|
|
GB201818761D0
|
|
Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
|
|
GB201810301D0
|
|
Combinatorial gene therapy
|
|
GB201809622D0
|
|
Engineering extracellular vesicles for affinity purification
|
|
GB201804291D0
|
|
Cell-mediated exosome delivery
|
|
GB201802163D0
|
|
Compositions for EV storage and formulation
|
|
GB201800921D0
|
|
Intracellular delivery of target silencing technology
|
|
GB201718681D0
|
|
Protein engineered extracellular vesicles
|
|
GB201718471D0
|
|
Exosomes comprising RNA therapeutics
|
|
GB201717446D0
|
|
Affinity purification of engineering extracellular vesicles
|
|
CN109715211A
|
|
Allochthon comprising therapeutical peptide
|
|
GB201702863D0
|
|
Improved loading of EVs with therapeutic proteins
|
|
GB201612643D0
|
|
Surface decoration of extracellular vesicles
|
|
GB201612110D0
|
|
EV-Mediated delivery of binding protein-small molecule conjugates
|
|
GB201611988D0
|
|
CPP-Mediated EV Loading
|
